Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


STOCKWATCH: Running the gamut of commotions from A to A

This article was originally published in Scrip

Executive Summary

As the third quarter earnings season got under way last week, bad news across the sector seemed to be focused on companies with names starting at the front of the alphabet, like Ariad, AMAG, Alimera Sciences and Amarin. But away from 'A', Johnson & Johnson's continuing good performance raised interesting questions not only for pharmaceutical firms, but also for their competitors in the devices or diagnostics sectors.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts